Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model

Journal of Oncology

Volumn , Issue , 2012, Pages

  Kauffman, Eric C ^a,b   Liu, Huixian ^a   Schwartz, Michael J ^c   Scherr, Douglas S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c The Arthur Smith Institute for Urology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD45 ANTIGEN; CYTOKINE; IMIDAZOQUINOLINE DERIVATIVE; INTERLEUKIN 6; KI 67 ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER INFILTRATION; CELL DEATH; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOCOMPETENCE; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NICK END LABELING; NONHUMAN; T LYMPHOCYTE; TUMOR GROWTH; XENOGRAFT;

EID: 84863362569     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/103298     Document Type: Article

References (42)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Sun M., Thuret R., Abdollah F., Lughezzani G., Schmitges J., Tian Z., Shariat S. F., Montorsi F., Patard J. J., Perrotte P., Karakiewicz P. I., Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis European Urology 2011 59 1 135 141
3. Motzer R. J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J., Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma Journal of Clinical Oncology 1999 17 8 2530 2540 (Pubitemid 29368255)
4. Motzer R. J., Rini B. I., Bukowski R. M., Curti B. D., George D. J., Hudes G. R., Redman B. G., Margolin K. A., Merchan J. R., Wilding G., Ginsberg M. S., Bacik J., Kim S. T., Baum C. M., Michaelson M. D., Sunitinib in patients with metastatic renal cell carcinoma Journal of the American Medical Association 2006 295 21 2516 2524 (Pubitemid 43854967)
5. Ratain M. J., Eisen T., Stadler W. M., Flaherty K. T., Kaye S. B., Rosner G. L., Gore M., Desai A. A., Patnaik A., Xiong H. Q., Rowinsky E., Abbruzzese J. L., Xia C., Simantov R., Schwartz B., O'Dwyer P. J., Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma Journal of Clinical Oncology 2006 24 16 2505 2512 (Pubitemid 46630627)
6. Freed S. Z., Halperin J. P., Gordon M., Idiopathic regression of metastases from renal cell carcinoma Journal of Urology 1977 118 4 538 542 (Pubitemid 8227391)
7. Medical Research Council Renal Cancer Collaborators, Interferon- and survival in metastatic renal carcinoma: early results of a randomised controlled trial The Lancet 1999 353 9146 14 17
8. McDermott D. F., Update on the application of interleukin-2 in the treatment of renal cell carcinoma Clinical Cancer Research 2007 13 2 716s 719s (Pubitemid 46220096)
9. Finke J. H., Rayman P., Hart L., Alexander J. P., Edinger M. G., Tubbs R. R., Klein E., Tuason L., Bukowski R. M., Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon- secretion, and proliferation Journal of Immunotherapy 1994 15 2 91 104 (Pubitemid 24047541)
10. Melief C. J. M., Kast W. M., T-cell immunotherapy of cancer Research in Immunology 1991 142 5-6 425 429
11. Yang L., Carbone D. P., Tumor-host immune interactions and dendritic cell dysfunction Advances in Cancer Research 2004 92 13 27 (Pubitemid 39458111)
12. Finke J. H., Zea A. H., Stanley J., Longo D. L., Mizoguchi H., Tubbs R. R., Wiltrout R. H., O'Shea J. J., Kudoh S., Klein E., Bukowski R. M., Ochoa A. C., Loss of T-cell receptor chain and p56(lck) in T-cells infiltrating human renal cell carcinoma Cancer Research 1993 53 23 5613 5616 (Pubitemid 23360259)
13. Idoyaga J., Moreno J., Bonifaz L., Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands Cancer Immunology, Immunotherapy 2007 56 8 1237 1250 (Pubitemid 46947944)
14. Uematsu S., Akira S., Toll-like receptors and type I Interferons Journal of Biological Chemistry 2007 282 21 15319 15324 (Pubitemid 47093256)
15. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S., Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nature Immunology 2002 3 2 196 200 (Pubitemid 34141451)
16. Bourquin C., Hotz C., Noerenberg D., Voelkl A., Heidegger S., Roetzer L. C., Storch B., Sandholzer N., Wurzenberger C., Anz D., Endres S., Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance Cancer Research 2011 71 15 5123 5133
17. Stockfleth E., Trefzer U., Garcia-Bartels C., Wegner T., Schmook T., Sterry W., The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview British Journal of Dermatology 2003 149 66, supplement 53 56 (Pubitemid 38064520)
18. Butchi N. B., Pourciau S., Du M., Morgan T. W., Peterson K. E., Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists Journal of Immunology 2008 180 11 7604 7612
19. Astry C., Birmachu W., Harrison L. I., Meng T. C., Cutaneous pharmacodynamics of a toll-like receptor 7 agonist, 852A, in humans Journal of Clinical Pharmacology 2008 48 6 755 762 (Pubitemid 351713151)
20. Naylor M. F., Crowson N., Kuwahara R., Teague K., Garcia C., Mackinnis C., Haque R., Odom C., Jankey C., Cornelison R. L., Treatment of lentigo maligna with topical imiquimod British Journal of Dermatology 2003 149 66, supplement 66 69 (Pubitemid 38064524)
21. Rajpar S. F., Marsden J. R., Imiquimod in the treatment of lentigo maligna British Journal of Dermatology 2006 155 4 653 656 (Pubitemid 44352542)
22. Utikal J., Zimpfer A., Thoelke A., Figl R., Hildenbrand R., Kettelhack C., Goerdt S., Schadendorf D., Ugurel S., Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod British Journal of Dermatology 2006 155 2 488 491 (Pubitemid 44050598)
23. Smith E. B., Schwartz M., Kawamoto H., You X., Hwang D., Liu H., Scherr D. S., Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder Journal of Urology 2007 177 6 2347 2351 (Pubitemid 46726385)
24. Schwartz M. J., Liu H., Hwang D. H., Kawamoto H., Scherr D. S., Antitumor effects of an imidazoquinoline in renal cell carcinoma Urology 2009 73 5 1156 1162
25. Enk A. H., Jonuleit H., Saloga J., Knop J., Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma International Journal of Cancer 1997 73 3 309 316 (Pubitemid 27508890)
26. Gabrilovich D. I., Corak J., Ciernik I. F., Kavanaugh D., Carbone D. P., Decreased antigen presentation by dendritic cells in patients with breast cancer Clinical Cancer Research 1997 3 3 483 490 (Pubitemid 27158075)
27. Ishida T., Oyama T., Carbone D. P., Gabrilovich D. I., Defective function of langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors Journal of Immunology 1998 161 9 4842 4851 (Pubitemid 28492062)
28. Nestle F. O., Burg G., Fh J., Wrone-Smith T., Nickoloff B. J., Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen- presenting cells American Journal of Pathology 1997 150 2 641 651 (Pubitemid 27073791)
29. Daurkin I., Eruslanov E., Stoffs T., Perrin G. Q., Algood C., Gilbert S. M., Rosser C. J., Su L. M., Vieweg J., Kusmartsev S., Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway Cancer Research 2011 71 20 6400 6409
30. Thompson R. H., Gillett M. D., Cheville J. C., Lohse C. M., Dong H., Webster W. S., Krejci K. G., Lobo J. R., Sengupta S., Chen L., Zincke H., Blute M. L., Strome S. E., Leibovich B. C., Kwon E. D., Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target Proceedings of the National Academy of Sciences of the United States of America 2004 101 49 17174 17179 (Pubitemid 39627793)
31. Schn M. P., Schn M., Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod Apoptosis 2004 9 3 291 298
32. Strominger N. L., Brady R., Gullikson G., Carpenter D. O., Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation Brain Research Bulletin 2001 55 3 445 451 (Pubitemid 32727905)
33. Wu C. C. N., Hayashi T., Takabayashi K., Sabet M., Smee D. F., Guiney D. D., Cottam H. B., Carson D. A., Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand Proceedings of the National Academy of Sciences of the United States of America 2007 104 10 3990 3995 (Pubitemid 47181566)
34. Schn M., Schn M. P., The antitumoral mode of action of imiquimod and other imidazoquinolines Current Medicinal Chemistry 2007 14 6 681 687
35. Redondo P., Del Olmo J., Lpez-Diaz De Cerio A., Inoges S., Marquina M., Melero I., Bendandi M., Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions Journal of Investigative Dermatology 2007 127 7 1673 1680 (Pubitemid 46933436)
36. Abdel-Hady E. S., Martin-Hirsh P., Duggan-Keen M., Stern P. L., Moore J. V., Corbitt G., Kitchener H. C., Hampson I. N., Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy Cancer Research 2001 61 1 192 196 (Pubitemid 32095717)
37. Van Der Burg S. H., Piersma S. J., De Jong A., Van Der Hulst J. M., Kwappenberg K. M. C., Van Den Hende M., Welters M. J. P., Van Rood J. J., Fleuren G. J., Melief C. J. M., Kenter G. G., Offringa R., Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens Proceedings of the National Academy of Sciences of the United States of America 2007 104 29 12087 12092 (Pubitemid 47185634)
38. Winters U., Daayana S., Lear J. T., Tomlinson A. E., Elkord E., Stern P. L., Kitchener H. C., Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia Clinical Cancer Research 2008 14 16 5292 5299
39. Daayana S., Elkord E., Winters U., Pawlita M., Roden R., Stern P. L., Kitchener H. C., Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia British Journal of Cancer 2010 102 7 1129 1136
40. Forward N. A., Furlong S. J., Yang Y., Lin T. J., Hoskin D. W., Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells Journal of Leukocyte Biology 2010 87 1 117 125
41. Lu H., Wagner W. M., Gad E., Yang Y., Duan H., Amon L. M., Van Denend N., Larson E. R., Chang A., Tufvesson H., Disis M. L., Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade Journal of Immunology 2010 184 9 5360 5367
42. Clark R. A., Huang S. J., Murphy G. F., Mollet I. G., Hijnen D., Muthukuru M., Schanbacher C. F., Edwards V., Miller D. M., Kim J. E., Lambert J., Kupper T. S., Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells Journal of Experimental Medicine 2008 205 10 2221 2234